Uriprene® Degradable Temporary Ureteral Stent for Ureteral Diseases
This study is testing the Uriprene® Degradable Temporary Ureteral Stent. This stent is designed to help with drainage after a successful, uncomplicated ureteroscopy (a procedure to remove kidney or ureteral stones). Researchers want to see how well the stent works to allow drainage without further intervention, and how long it takes for the stent to degrade or pass out of the body. They are also looking at any side effects for up to 90 days. You may be able to join if you are between 21 and 80 years old, have had a successful ureteroscopy for kidney or ureteral stones, and meet other specific health criteria. The study aims to enroll 87 participants, but its current recruitment status is unclear.
- Study design
- This is a prospective, multi-center study that is not randomized. It aims to enroll 87 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for safety assessments through 90 days after the stent is placed.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
At a glance
Conditions
Where it's being run
4 sites across 4 statesStudy leadership
- Mitchell Humphreys, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Primary Effectiveness Endpoint defined as the presence of the stent during the first 48 hours48 hours
Study Success defined as adequate short-term urine drainage, defined as the presence of the stent in the ureter and the lack of surgical or invasive intervention to treat symptoms in the stented ureter during the first 48 hours following placement.
- Primary Safety Endpoint defined as assessment of adverse events through 90 days90 days
Assessment of Adverse Events through the 90-day follow-up period (incidence, relationship to device and severity) compared to the historical control degradable ureteral stent and plastic ureteral stents